BioVentrix Has Developed a Unique Way to Improve Heart Functionality

BioVentrix is getting closer to bringing its transcatheter-based structural cardiovascular device to treat heart failure to the U.S. The private company announced receiving FDA breakthrough device designation for the Revivent TC Transcatheter Ventricular Enhancement System. This designation can help put San Ramon, CA-based BioVentrix on a faster path to obtaining FDA approval. The firm’s Revivent TC System is used in the Less Invasive Ventricular Enhancement (LIVE) procedure, to exclude scar tissue on the left ventricle that has resulted from a heart attack, so the healthy portion of the heart can function more efficiently. Micro-anchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has the potential to improve blood flow throughout the body. In an interview with MD+DI on Tuesday, Ken Miller, BioVentrix CEO, spoke about the nature of the problem the company was trying to solve and how stenting is creating a market for the device. “There are a million or so patients in the U.S. and many more that have heart attacks every year,” Miller told MD+DI. “Many of those patients either don’t know they’re having heart attacks and get to the hospital too late to be stented, or they get there and have a stent either later or on time and the stent doesn’t work forever. This will typically result in the ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news